# MGC Pharmaceuticals formally changes its name to Argent BioPharma Ltd

- Link: https://www.directorstalkinterviews.com/mgc-pharmaceuticals-formally-changes-its-name-to-argent-biopharma-ltd/4121149663
- Published: 2024-04-02T15:58:00+01:00
- Author: Amilia Stone

Argent BioPharma Ltd (ASX:RGT), an innovative drug discovery company within the 
biopharmaceutical sector, has formally changed its name from MGC Pharmaceuticals
Limited (ASX:MXC) to Argent BioPharma Limited as approved by shareholders at a General
Meeting held 18 March 2024.

**Change of name to Argent BioPharma Ltd**

The name change has been processed by the Australian Securities and Investments 
Commission and will take effect on the ASX from commencement of trading on **Wednesday,
3 April 2024**. The Company’s ASX code will migrate to **RGT**.

The name change will have a delayed effective date in the UK due to additional regulatory
requirements that can only be met after the effective date on the ASX, the anticipated
effective date of change for the UK is **10 April 2024**. The Company’s new ISIN
and TIDM are **AU0000326647** and **RGT** respectively.

The Company’s website address is now [www.argentbiopharma.com](http://www.argentbiopharma.com/).

Shareholders should note that their shareholdings will be unaffected by the change
of name. Existing share certificates should be retained as they will remain valid
for all purposes and no new share certificates will be issued.

**Company Overview**

In a notable milestone signalling the conclusion of its restructuring process, supported
by a substantial injection of capital and a comprehensive operational transformation,
Argent BioPharma is set to position itself as a significant player in pioneering
drug discovery within the biopharmaceutical sector. With dual listings on both the
London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is poised
to make a considerable impact in advancing medical treatment accessibility, harnessing
sophisticated methodologies in PolyPharmacology and Nanotechnology.

As a key pillar of Argent BioPharma’s philosophy, the Company embraces PolyPharmacology,
an innovative methodology focused on crafting and implementing therapeutics to influence
numerous molecular targets simultaneously. This approach plays a pivotal role in
effectively tackling the intricacies of multifaceted diseases, thereby establishing
a pioneering benchmark in both drug development and therapeutic effectiveness.

**Operational Highlights**

Argent BioPharma is positioned to generate revenue through its Investigational Medicinal
Products (IMPs), CannEpil® and CimetrA®, which are accessible to patients through
early access schemes in key markets including the UK, USA, and Europe. These initiatives
are further supported by real-world data obtained from early access treatments, 
offering valuable insights into safety and efficacy that bolster clinical trial 
outcomes.

Argent BioPharma’s European research hub is a key asset, playing a crucial role 
across the drug development continuum from conceptualisation to commercialisation.
The hub operates from two distinct manufacturing facilities; one dedicated to clinical
trials and early access programmes; and the other geared towards large-scale commercial
production. Argent BioPharma adheres rigorously to stringent EU GMP and GDP guidelines.

**Product Portfolio**

Argent BioPharma places special emphasis on its product range targeting immunology
and neurology, utilising PolyPharmacology to innovate novel treatments. Committed
to addressing unmet medical needs, the Company aims to introduce new treatment every
four years. Key products include CannEpil® for refractory epilepsy and cerebral 
palsy, CimetrA® for acute lung injury and ARDS, and CogniCann® for enhancing the
quality of life in dementia and Alzheimer’s patients, with additional treatments
in development.

**Roby Zomer, Managing Director and CEO of Argent BioPharma, commented:** “As Argent
BioPharma emerges from MGC Pharma, it is well positioned in the new era in biopharmaceuticals,
committed to providing accessible and impactful healthcare solutions on a global
scale. This rebranding signifies our commitment to innovation and advancement in
the biopharmaceutical landscape. We are excited to leverage our expertise in PolyPharmacology
and Nanotechnology to pioneer ground-breaking treatments, addressing unmet medical
needs and driving positive change in global healthcare.”

Share on: